Prima Biomed Ltd (PBMD) 0.90 $PBMD Prima BioMed

New Post Public Reply Private Reply Replies (0) Message Board

Aug 2, 2016 at 2:19 AM

Prima Biomed Ltd (PBMD) 0.90 $PBMD

Prima BioMed Collaborates in Investigator Sponsored New Clinical Trial for IMP321 in Solid Tumors
Marketwire Canada - Tue Jul 12, 2:40AM CDT
SYDNEY, AUSTRALIA--(Marketwired - Jul 12, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) today announced a new collaborative study investigating the intra-tumoural injection of IMP321. The investigator sponsored study will be conducted by the Institute of Clinical Cancer Research, Krankenhaus Nordwest GmbH in Frankfurt Germany ("IKF"; Institute for clinical oncology research at the Northwest University Hospital in Frankfurt). The new study will explore the potential for IMP321 as an activator of dendritic cells found within solid cancer tumours.
PBMD: 0.90 (-0.03)

Prima Reports Favorable Initial Breast Cancer Study Data
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 2:30PM CDT
Prima BioMed Ltd (PBMD) announced initial data from a phase IIb chemo-immunotherapy study on IMP321 for the treatment of metastatic breast cancer.
PBMD: 0.90 (-0.03), ANIP: 61.06 (+0.46), RTRX: 18.17 (+0.24), CELG: 114.69 (+2.50)

Prima BioMed to Maintain NASDAQ Listing
Marketwired - Mon Jun 06, 8:25PM CDT
SYDNEY, AUSTRALIA--(Marketwired - Jun 6, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) the "Company" has received notification from the Listing Qualifications Department of the NASDAQ Stock Market indicating that the Company's American Depositary Shares have maintained a closing bid price of US$1.00 per share or greater for 10 consecutive business days from 20 May 2016 to 3 June 2016. Accordingly, the Company has regained compliance with NASDAQ Listing Rule 5450(a)(1) (the "Minimum Bid Price Rule"

and the Company's American Depositary Shares will remain listed on the NASDAQ Global Market.
PBMD: 0.90 (-0.03)

Prima BioMed Enters Into Sale and Licensing Agreement With Sydys to Advance CVac(TM) Program
Marketwired - Thu May 12, 3:26AM CDT
SYDNEY, AUSTRALIA and SEATTLE, WA--(Marketwired - May 12, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)
PBMD: 0.90 (-0.03)

Prima BioMed Limited (NASDAQ: PBMD) Analyst Coverage Initiated
ACCESSWIRE - Tue May 03, 7:05AM CDT
SYDNEY, AUSTRALIA / ACCESSWIRE / May 3, 2016 / Prima BioMed Limited (NASDAQ: PBMD) an Australia-based biotechnology company engaged in research, development and commercialization of licensed medical biotechnology, recently announced the granting of patent number 5908210 entitled "Use of Recombinant LAG-3 or the Derivatives thereof for Eliciting Monocyte Immune Response" by the Japanese Patent Office. This patent relates to Prima's IMP321 and its use either alone, or in combination, for immunotherapeutic or chemotherapeutic purposes to induce an increase in circulating monocyte numbers in order to protect against cancer. This patent will therefore support the use of IMP321 as it is being used in Prima's AIPAC trial in metastatic breast cancer. Patent expiry is expected to be 3rd of October 2028.
PBMD: 0.90 (-0.03)

Top Stocks on 4/20: Investors Are Considering These on Wednesday April 20th
ACCESSWIRE - Wed Apr 20, 11:57AM CDT
MIAMI, FL / ACCESSWIRE / April 20, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. EBIO, ASM, OCLS, and PBMD have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
PBMD: 0.90 (-0.03), EBIO: 3.80 (-0.17), OCLS: 3.90 (-0.39)

IMP321 Safety and Immune Monitoring Data Published in Clinical Cancer Research Journal
Marketwired - Tue Mar 15, 2:40AM CDT
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) advises that safety and immune monitoring data from an investigator-led clinical trial in melanoma using IMP321 as an adjuvant to a therapeutic vaccine has been published in the March 15 edition of the Clinical Cancer Research journal. The paper is titled "Vaccination with sLAG-3-Ig (IMP321) and peptides induces specific CD4 and CD8 T-cell responses in metastatic melanoma patients: report of a phase I/IIa clinical trial" and is the result of a long-standing academic collaboration between Dr. Frederic Triebel, Prima's Chief Scientific Officer and Chief Medical Officer and scientists at the Ludwig Centre for Cancer Research at the University of Lausanne, Switzerland.
PBMD: 0.90 (-0.03)

Prima Biomed (PBMD) Jumps: Stock Adds 25.6% in Session
Zacks Equity Research - Zacks Investment Research - Fri Mar 11, 7:15AM CST
Prima Biomed Ltd. (PBMD) shares rose almost 26% in the last trading session.
PBMD: 0.90 (-0.03), ANIK: 50.64 (+0.72)

Prima BioMed wins US patent for IMP731 Antibody
M2 - Thu Jan 28, 3:34AM CST
Biotechnology company Prima BioMed (ASX

RR) (NASDAQ

BMD) disclosed on Wednesday the receipt of the patent entitled "Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease" from the US Patent and Trademark Office.
PBMD: 0.90 (-0.03)

US Patent Grants for IMP731 Antibody
Marketwired - Wed Jan 27, 5:00PM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company"

announces the granting of patent number US 9,244,059 entitled "Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease" by the United States Patent and Trademark Office.
PBMD: 0.90 (-0.03)

Prima BioMed to start Phase I melanoma study of IMP321 across Australia
M2 - Wed Jan 27, 3:16AM CST
Immuno-oncology company Prima BioMed (ASX

RR) (NASDAQ

BMD) announced on Tuesday that TACTI-mel, a Phase I clinical study in melanoma using its lead compound IMP321, will now commence in the Gallipoli Medical Research Foundation at the Greenslopes Private Hospital in Queensland, Austrlaia.
PBMD: 0.90 (-0.03)

Prima BioMed Initiates Phase I Melanoma Study in Australia
Marketwired - Tue Jan 26, 4:51PM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD), a leading immuno-oncology company, is pleased to announce the initiation of the first clinical trial site for TACTI-mel, a Phase I clinical study in melanoma using its lead compound IMP321, to be conducted in Australia.
PBMD: 0.90 (-0.03)

Prima BioMed Initiates Phase IIb Study in Metastatic Breast Cancer
Marketwired - Tue Dec 22, 6:00AM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)
PBMD: 0.90 (-0.03)

4 Stocks to Watch Trading Under $500M Market Cap
ACCESSWIRE - Fri Dec 11, 8:51AM CST
NEW YORK, NY / ACCESSWIRE / December 11, 2015 / MomentumStockAlert.com is a newsletter alert service that focuses on companies on the NASDAQ & NYSE. We only highlight quality companies with big potential. This commitment provides our subscribers with only the best recommendations of companies for short and long-term investments. Receive our free trade alerts via text message (SMS) and/or email at www.MomentumStockAlert.com. Today we are focusing on four companies to watch that have been attracting the attention of major investors.
EYES: 3.96 (-0.08), PBMD: 0.90 (-0.03), CGEN: 6.91 (+0.26), ONTY: 1.21 (+0.02)

Prima BioMed Progresses Japanese Collaboration
Marketwired - Fri Dec 11, 6:00AM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) today announces important progress in its collaboration with NEC Corporation and Yamaguchi University in Japan. In this collaboration, first announced in May 2015, Prima's IMP321 Antigen Presenting Cell activator (APC) is being combined with a therapeutic vaccine for different carcinoma types that was developed at Yamaguchi University.
PBMD: 0.90 (-0.03)

Prima BioMed Unveils Phase I Combination Study of IMP321 + Checkpoint Inhibitor
Marketwired - Wed Nov 18, 6:00AM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)
PBMD: 0.90 (-0.03)

Prima BioMed announces AUD2.0m from equity placement with an Australian Institution
M2 - Mon Nov 02, 4:19AM CST
Immuno-oncology company Prima BioMed (ASX

RR) (NASDAQ

BMD) said on Friday that it has raised AUD2.0m in an equity placement with an Australian Institution.
PBMD: 0.90 (-0.03)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cut Winter Heating Costs with Townsend's Rebate Help

Unseen Perils of Winter Heating in Massachusetts Massachusetts homeowners, listen up. If your heating system is older than the Model T, it's time to rethink your winter strategy. You don't want to be stuck in the cold when the thermometer hits single digits, do you? That's where Townsend comes in, making waves with their rebate assistance program. Navigating the Rebate...

Endurance Energy's Modular Tech Revs Up Southeast Asia

Modular Solutions Steal the Show in Bangkok When a company draws 59,468 attendees from over 150 countries, folks pay attention—and that was exactly the scene at Gastech 2026 in Bangkok. The name buzzing on many lips? Endurance Energy. These guys showcased a fresh take on energy logistics with their skid-mounted liquefaction tech, turning heads with their Southeast Asia...

Geron Corp Faces Fiduciary Duty Investigation

Spotlight on Geron's Corporate Governance: What's Happening? The heat's been turned up on Geron Corporation this week, with Halper Sadeh LLC, an investor rights law outfit, digging into whether some folks at the helm have strayed from their fiduciary duties to the shareholders. Now, if you're holding onto NASDAQ:GERN stock or thinking about diving in, it's high time to...

AST SpaceMobile Faces Class Action Over Misstatements

What's Going On with AST SpaceMobile? Kicking off with a heavy hitter here, folks. AST SpaceMobile, Inc., trading under NASDAQ:ASTS, is under a securities fraud spotlight. We're talking allegations piled higher than a morning stack of pancakes. If you picked up any ASTS shares between March 4, 2025, and July 15, 2026, you're in on this rough ride. There's a class action...

Krispy Kreme Faces Legal Probe: Fiduciary Breach?

Diving Deep into the Krispy Kreme Allegations Look, this isn't your run-of-the-mill donut drama. When you hear rumblings of corporate missteps, especially ones that involve potential breaches of fiduciary duties, it's time to perk up those ears. Over at Krispy Kreme, Inc. (NASDAQ:DNUT), there's some heat in the kitchen, and it's not just from frying those glazed beauties....

CVS Health Under Fire: Fiduciary Duty Breach?

CVS Under Regulatory Spotlight for Fiduciary Breaches You'd think by now companies would have their fiduciary ducks in a row. But here we are, with CVS Health Corporation (NYSE: CVS) catching heat from the legal eagles over at Halper Sadeh LLC. The knife’s out for some of the big wigs – apparently, there's chatter they might’ve slipped on their duty to play nice...

Timur Turlov Leads FIDE with Chess and Digital Focus

An Unpredicted Victory in Samarkand Well, color me surprised. Timur Turlov's made waves by clinching the role of FIDE President at the General Assembly in Samarkand. This one's quite the turn for the chess world—Kazakhstan’s own stepping up to run the whole show. This isn't just some ceremonial post either. Turlov, who's been pulling strings over at the Kazakhstan...

HONA Faces Legal Heat: Investor Lawsuit Over Losses

The Investor Storm Brewing Over Honeywell Aerospace There it is again, another industry heavyweight caught in a dizzying whirlwind of litigation. Honeywell Aerospace Inc. (NASDAQ:HONA), a name as established as an old boot in the business, now faces a class action lawsuit that's got investors frantically dusting off phone numbers for their attorneys. The Messy Allegations...

Quay Sunglasses: Luxury Looks, Affordable Prices

Ah, sunglasses—the quintessential accessory that screams both practicality and style. A million-dollar look without the million-dollar expense? That's where Quay comes in. They've been recognized by Expert Consumers, no less, as some of the best-in-class for affordable luxury eye candy out there—aimed at shoppers who want the designer vibe without the hemorrhaging...

China Southern Airlines Marks 70th Anniversary in NYC

Taking Flight with Legacy and Tradition Throwing a bash on Times Square isn't just about flash; it's about letting folks know you mean business. And China Southern Airlines has been doing just that for 70 years. Imagine starting from Guangzhou and ending up splashed across New York City's giant LED screens—talk about a journey! From Humble Roots to Global Network...